TOP > 外国特許検索 > PEPTIDE THAT SPECIFICALLY ACCUMULATES IN BILIARY TRACT CANCER, AND USE THEREOF

PEPTIDE THAT SPECIFICALLY ACCUMULATES IN BILIARY TRACT CANCER, AND USE THEREOF

外国特許コード F170009073
整理番号 (S2015-1988-N26)
掲載日 2017年5月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP078607
国際公開番号 WO 2017057450
国際出願日 平成28年9月28日(2016.9.28)
国際公開日 平成29年4月6日(2017.4.6)
優先権データ
  • 特願2015-196227 (2015.10.1) JP
発明の名称 (英語) PEPTIDE THAT SPECIFICALLY ACCUMULATES IN BILIARY TRACT CANCER, AND USE THEREOF
発明の概要(英語) The present invention provides a novel peptide that specifically accumulates in biliary tract cancer. The peptide according to the present invention is (a) a peptide having an amino acid sequence containing a sequence represented by SEQ ID NO. 1, or (b) a peptide having an amino acid sequence containing a sequence having an identity of 60% or more with respect to the sequence represented by SEQ ID NO. 1, and specifically accumulates in biliary tract cancer.
従来技術、競合技術の概要(英語) BACKGROUND ART
Biliary cancer, cholangiocarcinoma, gallbladder cancer, and duodenal cancer cancer composed of the nipple portion. Gall bladder cancer and bile duct cancer in Japan is the number of deaths, about 8,900 male person 2013 years, about 9,300 female person. Gall bladder cancer and cholangiocarcinoma (national estimate) number is suffering from, 2010 years, about 11,300 male and female example example about 11,300, 2% and 3% each occupy the entire number of suffering from cancer. In addition, in the gall bladder and bile duct cancer patients, surgical procedures may be applied between about 20% and, further, after surgery 30% years survival rate of from about 5 in. Biliary cancer is, almost no subjective symptoms at an early, jaundice, white stool, urine jaundice, abdominal pain and the like at the point of the appearance of symptoms which has proceeded to some extent, is found at an early stage is important in the treatment. It should be noted that, in the present specification histopathologically biliary bile duct cancer is adenocarcinoma of epithelial origin, gland squamous cell carcinoma, intrahepatic bile duct cell carcinoma which includes the.
Biliary cancer (in particular, in liver or extra-hepatic bile duct epithelial-derived cancer) of the test and diagnosis method, blood biochemical tests, abdominal ultrasound, abdominal contrast CT inspection, endoscopic retrograde to insert the angiographic (ERCP: endoscopic retrograde cholangiopancreatography), FDG-PET and the like inspection (Fluorodeoxy glucose-Positron Emission Tomography).
However, the peptide is utilized as a biomaterial in the trend in the medical field, Tat, penetratin, polyarginine such as a cell-membrane permeable peptide (cell-absorbable) is drawing attention. However, these peptides, tumor cells or normal cells or normal tissue and tumor tissue as well as the diffuse and non-selectively absorbed, requires the delivery of drug target selection to the treatment of malignant tumors (Drag Delivery System) apply the tool DDS, cause serious side effects in that it is difficult to use. In particular, worldwide Tat on a general-purpose experimental system such as a cell-membrane permeable (a cell-absorbable) peptide, the nature that gives rise to the liver has been known (for example, see non-patent document 1). On the other hand, the cyclic RGD, has been the only peptide pharmaceutical. Is cyclic RGD, or an existing blood vessel endothelial cells of angiogenic blood vessels (and in some tumor cells) is highly expressed in reported αv β3 which targets integrin, upregulation of vascular permeability due to its action point, without a simultaneous combination alone in the form of other pharmaceutical and or imaging agents have been applied as DDS (for example, see Patent Document 1.).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NIIGATA UNIVERSITY
  • 発明者(英語)
  • KONDO Eisaku
  • SAITO Ken
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close